Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical potency and a greater than three-fold increase in non-human primate half-life compared to risankizumab  Accelerated expected initiation of first-in-human trial for SPY003 to the first quarter of 2025 $414 million of cash, cash equivalents, and marketable securities as of September 30, 2024, with expected runway well into 2027, through multiple clini

WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr. Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation and Immunology. This includes more than 15 years

Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an anti-TL1A antibody program designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human trials in the second half of 2024 Nominated a development candidate for SPY003, a highly potent anti-IL-23 antibody with an extended half-life compared to existing molecules, with expectations to begin a first-in-human trial in the first half of 2025 $426 million of cash, cash equivalents, marketable securities

WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced the appointment of Sandra Milligan, M.D., J.D., President of Aspira Women's Health, to its Board of Directors. "With a distinguished career spanning leadership roles at large and small biopharmaceutical companies, Dr. Milligan brings deep expertise in clinical development and regulatory affairs, including within IBD, that will be invaluable as we execute o

SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains on track to begin first-in-human studies in the second quarter of 2024, with interim proof-of-concept data expected year-end 2024 SPY002, an anti-TL1A antibody designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human studies in the second half of 2024 Raised $180 million in a March 2024 private placement equity financing with participation from new and existing investors $485 million of cash, cash equivalents, marketable securities, and restricted cash

Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the symbol "SYRE" SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing, demonstrated an updated half-life of 22 days, a greater than three-fold increase relative to vedolizumab in non-human primate pharmacokinetic data recently presented at ECCO; remains on track to begin first-in-human studies in the first half of 2024, with interim proof-of-concept data expected year-end 2024 SPY002, an anti-TL1A antibody designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing m

Wedbush initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $45.00

Evercore ISI initiated coverage of Spyre Therapeutics with a rating of Outperform

Robert W. Baird initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $50.00

Wells Fargo upgraded Spyre Therapeutics from Equal Weight to Overweight and set a new price target of $35.00 from $12.00 previously

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13D/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

424B5 - Spyre Therapeutics, Inc. (0001636282) (Filer)

424B5 - Spyre Therapeutics, Inc. (0001636282) (Filer)

10-Q/A - Spyre Therapeutics, Inc. (0001636282) (Filer)

10-Q/A - Spyre Therapeutics, Inc. (0001636282) (Filer)

10-Q/A - Spyre Therapeutics, Inc. (0001636282) (Filer)

10-K/A - Spyre Therapeutics, Inc. (0001636282) (Filer)

8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

S-8 - Spyre Therapeutics, Inc. (0001636282) (Filer)

8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the pricing of its previously announced underwritten public offering of 7,275,000 shares of its common stock at a price to the public of $27.50 per share. The aggregate gross proceeds to the Company from this offering are expected to be $200.0 million, before deducting underwriting discounts and commissions and othe

WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced that it has commenced an underwritten public offering of up to $200.0 million of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option fo

SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase relative to vedolizumab, supporting potential Q6M maintenance dosing with a single subcutaneous (SC) injection Planned Phase 2 induction regimen targets drug concentrations in quartile 4 of vedolizumab's exposure-response relationship, which has the potential to increase or accelerate efficacy Single, lowest dose of SPY001 led to complete saturation of α4β7 receptors through Week 12 (longest follow-up available for pharmacodynamic data) Company plans to initiate a platform Phase 2 trial in mid-2025 that will include SPY001, follow

WALTHAM, Mass., Nov. 11, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced it will report interim results from the Phase 1 SPY001 healthy volunteer trial on Tuesday, November 12, 2024. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre

Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical potency and a greater than three-fold increase in non-human primate half-life compared to risankizumab  Accelerated expected initiation of first-in-human trial for SPY003 to the first quarter of 2025 $414 million of cash, cash equivalents, and marketable securities as of September 30, 2024, with expected runway well into 2027, through multiple clini

WALTHAM, Mass., Nov. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 90,000 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2

WALTHAM, Mass., Oct. 30, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim's Inaugural Healthcare Innovation ConferenceDate: Wednesday, November 13, 2024Time: 2:30pm ET Event: Stifel 2024 Healthcare ConferenceDate: Monday, November 18, 2024Time: 1:15 pm ET Event: Jefferies London Healthcare ConferenceDate: Wednesday, N

SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented at UEGW demonstrating robust preclinical activity including comparable potency and a greater than three-fold extension in half-life in NHPs relative to risankizumab1. Spyre portfolio now uniquely includes extended half-life molecules targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing. Additional preclinical data on SPY003 in combination with SPY001 or SPY002 presented at UEGW showing enhanced preclinical efficacy and pharmacodynamics WALTHAM, Mass., Oct. 14, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:

WALTHAM, Mass., Oct. 4, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of (i) stock options to purchase 400,000 shares of common stock of Spyre to Dr. Sheldon Sloan in connection with his appointment as Chief Medical Officer and (ii) stock options to purchase an aggregate of 129,000 shares of c

WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr. Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation and Immunology. This includes more than 15 years

Evercore ISI Group analyst Umer Raffat initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Outperform rating.

Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or twelve weeks compared to dosing every two weeks for subcutaneous vedolizumab. SPY002, an extended half-life anti-TL1A antibody designed for enhanced potency to both TL1A monomers and trimers, remains on track to begin first-in-human studies in the second half of 2024. All three next-generation antibodies targeting α4β7, TL1A, and IL-23 are on track to be in the clinic within 12 months, each serving as backbones for potential best-in-class combinations

Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture. Paragon will not conduct any new campaigns that generate anti-α4ß7 or anti-TL1A monospecific antibodies for at least 5 years. The Company will pay Paragon a low single-digit percentage royalty for single antibody products and a mid single-digit percentage royalty for products containing more than one antibody from Paragon. There is a royalty step-down of 1/3rd if there is no Paragon patent in effect during the royalty term. The royalty term ends on the later of (i) the last-to-expire licensed patent or Company patent directed to a der

Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and raises the price target from $35 to $40.

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $32 to $40.

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(1.17) by 2.56 percent.

Baird analyst Colleen Kusy initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Outperform rating and announces Price Target of $50.

Stifel analyst Alex Thompson reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $36 to $54.

Stifel analyst Alex Thompson maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $36 to $54.